免疫治疗中的研究性药物:多发性骨髓瘤治疗的新视野
过去5年新一代蛋白酶体抑制剂(卡非佐米、伊沙佐米)和免疫调节衍生物(泊马度胺)显著影响患者结局,但多发性骨髓瘤仍因克隆异质性和骨髓微环境复杂相互作用而高度耐药。2015年达雷妥尤单抗和埃罗妥珠单抗获批后,即使在重度预处理患者中也观察到持久缓解,提示免疫学方法具有真实价值。本文综述正在研究中的新型单克隆抗体和嵌合抗原受体(CAR)T细胞策略。
要点
- 新一代蛋白酶体抑制剂和免疫调节衍生物显著影响多发性骨髓瘤患者结局。
- 多发性骨髓瘤因克隆异质性和骨髓微环境相互作用仍高度耐药,几乎所有患者最终复发。
- 2015年获批的达雷妥尤单抗和埃罗妥珠单抗在重度预处理患者中观察到持久缓解。
核心结论
- 免疫学方法在多发性骨髓瘤治疗中具有真实价值,本综述聚焦正在研究中的新型单克隆抗体和CAR T细胞策略。
研究设计与样本
- 综述,聚焦处于不同临床开发阶段的新型单克隆抗体和嵌合抗原受体(CAR)T细胞策略。
主要发现
- 过去5年新一代蛋白酶体抑制剂(卡非佐米、伊沙佐米)和免疫调节衍生物(泊马度胺)的引入对患者结局产生实质性影响。
- 多发性骨髓瘤因克隆异质性和与周围骨髓微环境的复杂相互作用而仍高度耐药,几乎所有患者在对蛋白酶体抑制剂、免疫调节衍生物或两者产生治疗反应后最终复发。
- 2015年达雷妥尤单抗和埃罗妥珠单抗获监管批准后,即使在已耗尽其他治疗选择的重度预处理患者中也观察到印象深刻且持久的缓解。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The treatment of multiple myeloma (MM) has gone through several major advances over the last 5 years with the introduction of next generation proteasome inhibitors (PI; carfilzomib, ixazomib) and immunomodulatory derivatives (IMiD; pomalidomide), with these new agents having a substantial impact on patient outcome. However, despite these advances, MM remains a highly resistant disease given its propensity for clonal heterogeneity and its complex interaction with the surrounding bone marrow microenvironment. Almost all patients eventually relapse despite therapeutic responses to a PI, IMiD or both. With the regulatory approval of the monoclonal antibodies Daratumumab and Elotuzumab in 2015, impressive and durable responses are being observed, even in heavily pre-treated patients who have exhausted other therapeutic options, suggesting immunological approaches in this setting have real merit. This review will focus on newer monoclonal antibodies and chimeric-antigen receptor (CAR) T cell strategies currently under investigation and in various stages of clinical development.
引用
- Varga C, Laubach JP, Anderson KC, et al. Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma. Br J Haematol. 2018. PMID: 29748955. doi:10.1111/bjh.15116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。